Recurrence of hepatitis C virus after treatment with pegylated interferon and direct acting antivirals in Punjab Pakistan

Raza, M. N; Sughra, K; Zeeshan, N; Anwar, M. Z; Shahzad, M. A; Rashid, U; Afroz, A; Munir, H.
Braz. j. biol ; 83: 1-6, 2023. ilus, graf, tab
Artículo en Inglés | LILACS, VETINDEX | ID: biblio-1469016

Documentos relacionados

  1. Recurrence of hepatitis C virus after treatment with pegylated interferon and direct acting antivirals in Punjab Pakistan
  2. Association between inosine triphosphatase rs1127354 polymorphisms and ribavirin-induced anaemia and outcome in hepatitis C virus-infected patients: A meta-analysis.
  3. Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient.
  4. Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving fixed-dose pangenotypic direct-acting antivirals.
  5. Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis.
  6. Implications of HCV RNA level at week 4 of direct antiviral treatments for hepatitis C.
  7. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment.
  8. Genetic variants in the apoptosis gene BCL2L1 improve response to interferon-based treatment of hepatitis C virus genotype 3 infection.
  9. Hepatitis C virus serologic relapse after treatment with direct-acting antivirals is dependent on viral RNA levels in peripheral blood mononuclear cells and the grade of liver cirrhosis.
  10. Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.